A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia
NCT07615426
This study is recruiting at 8 US sites in 6 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to see how feasible it is to enroll participants with schizophrenia and for them to complete the study/assessments. It will also assess how safe and tolerable aticaprant is when compared with placebo in participants with schizophrenia.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Schizophrenia
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 to 55 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Janssen Research & Development, LLC
- Last updated on ClinicalTrials.gov
- September 28, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- CNS Network · Garden Grove, CA
Georgia · 1
- Synexus Clinical Research US Inc · Atlanta, GA
Illinois · 1
- Uptown Research Institute · Chicago, IL
Michigan · 1
- Western Michigan University · Kalamazoo, MI
New York · 2
- Neurobehavioral Research Inc · Cedarhurst, NY
- Evolution Research Group · Staten Island, NY
Texas · 2
- Community Clinical Research, Inc. · Austin, TX
- Pillar Clinical Research, LLC · Richardson, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.